New Cloud Medical

New Cloud Medical (新云医疗) is a Beijing-based chronic-pain medical-device company founded in 2016 by CEO Zhao Yun, an eight-year hospital veteran . It positions itself as an integrated solutions provider for chronic pain, building a pipeline that runs from non-invasive transcutaneous electrical stimulation to minimally invasive instruments and active implantable devices—notably including an AI closed-loop spinal cord stimulator and a minimally invasive yellow-ligament resection kit that Dalton Venture says broke foreign monopolies in the field .

The company's stated model is "产学研医用" (industry-university-research-clinical-application), partnering with institutions such as the Chinese Academy of Sciences Electrical Engineering Institute and China Rehabilitation Research Center on Beijing municipal tech projects, and with Beijing University of Chemical Technology on novel medical materials . Its commercial focus sits on two registered product lines, NewStim® and NewMild®, and it is pursuing U.S. clinical trials and regulatory clearance as part of a push to take neuro-modulation devices global .

In September 2025 New Cloud Medical closed a Series B+ round of tens of millions of RMB led by Dalton Venture, with follow-on from Taizhou Angel Fund and Qianfeng Investment; Dalton partner Zhencheng Lin framed the bet as a long-term partnership to take breakthrough products worldwide . The company has raised six rounds in total since inception .